40. Application of Yamaguchi criteria on early diagnosis of systemic Juvenile Idiopathic Arthritis: A case report

Le Khanh Minh, Nguyen Thi Dieu Thuy, Nguyen Thi Thanh Mai, Ngo Thi Huyen Trang, Luong Thi Lien, Tran Duy Manh, Pham Van Duong, Nguyen Thi Dung, Tran Van Anh, Nguyen Thi Ha

Main Article Content

Abstract

Systemic Juvenile Idiopathic Arthritis (sJIA) is an infrequent auto-inflammatory disorder observed in pediatric patients, with clinical manifestations typically involve fever and arthritis, often accompanied by additional symptoms such as rash, generalized lymphadenopathy, hepatomegaly and/or splenomegaly, and serositis. Nevertheless, the initial presentation of sJIA frequently lacks specificity and may overlap other pathological entities. The 2001 criteria established by the International Society of Rheumatology, while widely employed, exhibit notable limitations particularly concerning atypical presentations, leading to the utilization of the Yamaguchi criteria to enhance the early detection of sJIA. We present a case involving a 14-year-old patient presenting persistent fever and distinctive cutaneous manifestations. Following the exclusion of alternative etiologies for fever, the patient fulfills the diagnostic criteria for systemic juvenile idiopathic arthritis according to the Yamaguchi criteria. In conclusion, this case highlights the effectiveness of Yamaguchi criteria in diagnosing sJIA, particularly in its early stages. This aids in prompt therapeutic interventions and mitigates potentially life-threatening complications.

Article Details

References

1. Beukelman T, Ringold S, Davis TE, et al. Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867-1874. doi:10.3899/jrheum.120110
2. Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343-348.
3. Davies R, Southwood T, Kearsley-Fleet L, et al. Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Arch Dis Child. 2017;102(2):206.2-207. doi:10.1136/archdischild-2016-311571
4. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.
5. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405-1413. doi:10.1002/art.38615
6. Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2012;10(1):40. doi:10.1186/1546-0096-10-40
7. Hashad SS, Etayari HM, Almsellati IA, et al. E27 Performance of systemic juvenile idiopathic arthritis classification criteria: one-centre experience-Libya. Rheumatology. 2023;62(Supplement_3):kead323.027. doi:10.1 093/rheumatology/kead323.027
8. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-430.
9. El Hamshary A, Marzouk H, Khalifa NM, et al. Relevance of application of the Yamaguchi criteria for patients with suspected juvenile idiopathic arthritis in the absence of arthritis symptoms. Reumatologia. 2014;52(6):362-368. doi:10.5114/reum.2014.47229
10. Petyy RE, Cassidy JT. Chronic arthritis. In: Cassidy JT, Petty RE, editors. Textbook of Pediatrik Rheumatology. 5th ed. Elsevier Saunders; 2005. pp. 206–341.
11. Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160-3169. doi:10.1002/art.38802
12. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421-426. doi:10.1136/adc.85.5.421
13. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566-576. doi:10.1002/art.39332
14. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. doi:10.1002/pbc.21039
15. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 2022;74(4):553-569. doi:10.1002/art.42037